Epigenetic biotech raises bumper round to the Tune of $175M to fund entry into clinic

Fecha de publicación: 13/01/2025
Fuente: FierceBiotech
Investors clearly appreciate the song that Tune Therapeutics is singing, handing over $175 million in series B funds as the biotech takes its epigenetic silencing drug into the clinic.